Targeted Radioimmunotherapy and Theranostics with Alpha Emitters.
Alpha targeted therapy
antibody
pretargeting
radioimmunotherapy
Journal
Journal of medical imaging and radiation sciences
ISSN: 1876-7982
Titre abrégé: J Med Imaging Radiat Sci
Pays: United States
ID NLM: 101469694
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
03
06
2019
revised:
12
07
2019
accepted:
16
07
2019
pubmed:
28
8
2019
medline:
11
7
2020
entrez:
28
8
2019
Statut:
ppublish
Résumé
Radiolabeled antibodies allow for selective targeting of the cancer cells within a tumor. Both beta- and alpha-emitting radioisotopes can be linked to the antibodies for delivery of radiation to the cells. The choice of the radionuclide would depend on the biological characteristics of the antibody including its biodistribution and biological half-life. Alpha-emitting isotopes deliver high energy to target sites within short range and therefore less radiation to adjacent normal tissues. Whole antibodies have long biological clearance times that may be limiting due to radiation levels to blood and marrow. Novel strategies, such as development of smaller antibody fragments such as minibodies and diabodies, which have faster biological clearance, engineered bispecific antibodies, and multistep targeting that uses pretargeting and bioorthogonal click chemistry methods, appear promising. Several novel targets are being investigated in early-phase studies. This review provides a brief summary and current status of radioimmunotargeted agents in oncology.
Identifiants
pubmed: 31451417
pii: S1939-8654(19)30348-0
doi: 10.1016/j.jmir.2019.07.006
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
S41-S44Informations de copyright
Copyright © 2019. Published by Elsevier Inc.